La thérapeute est chinoise et a effectué ses études dans le berceau de l'acupuncture. Elle parle le français et connaît bien le corps humain ce qui est un plus. Ce qui est super c'est qu'elle n'a pas de timing et si le soin doit durer, le prix est le même. Elle est très à l'écoute. Elle prend le temps de soigner et de soulager mes maux. Je la recommande fortement.

I have studied pharmacy with a partial focus on medicine and pursued advanced training over the years in the fields of genetics and cancer immunology. I am here to assist you in finding the best cancer therapy worldwide and guide you from your initial inquiry to the completion of the treatment. With 25 years of experience in Big Pharma and as the director of specialized clinics in Dubai, I have had the privilege of working alongside dedicated physicians and scientists who have successfully developed innovative cancer therapies. Today, I take pride in having them as part of our Iaso Cancer Initiative. Bruno Rosset

IBSA ( Institut Biochimique SA ) is a Swiss multinational pharmaceutical Company , founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents , through the Company’s 20 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 986 million CHF and employs over 2,300 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents , plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas : reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility .

Hirslanden is committed to high-quality, responsible and efficiently integrated healthcare that focuses on the needs of the individual. Working together with private and public cooperation partners, the Hirslanden Group prioritises ongoing development of the Continuum of Care concept. From birth to old age, from prevention to healing, Hirslanden is always there, both on a physical and digital level. Hirslanden differentiates itself from the rest of the market as a service provider with first-class medical and service quality, which is guaranteed by highly qualified independent specialists with years of experience who offer excellent care and services. Interdisciplinary medical centres of expertise, specialised institutes and competent cooperation partners enable optimal, personalised diagnosis and treatment, regardless of case complexity, in both inpatient and outpatient contexts. The Hirslanden Group operates 17 hospitals in 10 cantons, many of which have an emergency department. It also operates 5 outpatient surgery centres, 18 radiology and 6 radiotherapy institutes. The Group has 2,515 partner doctors and 11,025 employees, 551 of whom are permanently employed doctors. Hirslanden is the largest medical network in Switzerland. In the 2021/22 financial year, the Group generated turnover of CHF 1,885 million. As at 31 March 2022, the Group had treated 109,624 patients for a total of 472,301 inpatient days. The patient mix consists of 51.3% patients with basic insurance, 28.2% with semi-private insurance and 20.5% with private insurance. The Hirslanden Group was formed in 1990 through the merger of several hospitals. Since 2007, it has been part of the international hospital group Mediclinic International plc, which is listed on the London Stock Exchange.